Objectives The objective of this study was to explore the correlation between the distribution of traditional Chinese medicine(TCM)syndromes and molecular types of breast cancer in the perichemotherapy period.Methods ...Objectives The objective of this study was to explore the correlation between the distribution of traditional Chinese medicine(TCM)syndromes and molecular types of breast cancer in the perichemotherapy period.Methods A total of 325 cases with perichemotherapy breast cancer was classified according to syndrome differentiation in TCM,and R×C table x2 test was used to examine and analyze the relationship between TCM syndromes and molecular types of breast cancer in the perichemotherapy period.Results(1)In the early stage of chemotherapy,there was no significant difference in the distribution of different TCM syndromes among molecular types,mainly liver depression syndrome and liver depression and phlegm coagulation syndrome(p>0.05).(2)In the middle stage of chemotherapy,there were significant differences in the distribution of spleen deficiency and phlegm-dampness syndrome among HER-2 positive(HR positive),HER-2 positive(HR negative),and Luminal Atype,Luminal B type(HER-2 negative),and triple-negative type(p<0.01).(3)After chemotherapy,there were significant differences in the distribution of spleen and kidney yang deficiency syndrome and marrow sea insufficiency syndrome among HER-2 positive(HR negative),triple-negative type,and HER-2 positive(HR positive),Luminal A type,Luminal B type(HER-2 negative),and triple-negative type(p<0.01).Conclusion(1)In the middle stage of chemotherapy,HER-2 positive(HR positive)and HER-2 positive(HR negative)are more likely to show spleen deficiency and phlegmdampness syndrome than other molecular types.(2)In the late stage of chemotherapy,the HER-2 positive(HR negative)and triple-negative type is more likely to show spleenkidney yang deficiency syndrome than other molecular types,and the triple-negative type is more likely to show marrow sea insufficiency syndrome than other molecular types.展开更多
Type-Ⅱ InAs/GaSb superlattiees made of 13 InAs monolayers （MLs） and 7 GaSb MLs are grown on GaSb substrates by solid source molecular beam epitaxy. To obtain lattice-matched structures, thin InSb layers are inserte...Type-Ⅱ InAs/GaSb superlattiees made of 13 InAs monolayers （MLs） and 7 GaSb MLs are grown on GaSb substrates by solid source molecular beam epitaxy. To obtain lattice-matched structures, thin InSb layers are inserted between InAs and GaSb layers. We complete a series of experiments to investigate the influence of the InSb deposition time, Ⅴ/Ⅲ beam-equivalent pressure ratio and interruption time between each layer, and then characterize the superlattice （SL） structures with high-resolution x-ray diffraction and atomic force microscopy. The optimized growth parameters are applied to grow the 100-period SL structure, resulting in the full-width half-maximum of 29.55 arcsee for the first SL satellite peak and zero lattice-mismatch between the zero-order SL peak and the GaSb substrate peak.展开更多
Background: There are few clinical trials addressing the difference in pleiotropic effects among dipeptidyl peptidase (DPP)-4 inhibitors. We aimed to identify difference in effects on biochemical markers of inflammati...Background: There are few clinical trials addressing the difference in pleiotropic effects among dipeptidyl peptidase (DPP)-4 inhibitors. We aimed to identify difference in effects on biochemical markers of inflammation, oxidative stress, and atherosclerosis between two DPP-4 inhibitors in patients with type 2 diabetes. Methods: We prospectively observed twenty subjects with type 2 diabetes before and after a practical medication change from a treatment with pioglitazone and sitagliptin 50 mg to a combination tablet containing the same dose of pioglitazone and alogliptin 25mg, which was actually identical to switching from sitagliptin to alogliptin. After 3 months, changes from baseline in clinical data and various biochemical markers were evaluated. In particular, body mass index (BMI) and hemoglobin A1c (HbA1c) were additionally followed after 12 months for evaluation of chronic outcomes. Results: Among markers, serum levels of high molecular weight (HMW) adiponectin significantly increased from 6.9 ± 3.6 μg/ml to 8.2 ± 4.0 μg/ml (P = 0.0045). Although no clinical data changed after 3 months, significant improvements in HbA1c and BMI were observed after 12 months. Their rates of changes tended to inversely correlate with the increased percentages of serum HMW adiponectin levels during initial 3 months, but they did not reach statistical significance. Conclusions: In spite of pretreatment with pioglitazone, additional increase in serum HMW adiponectin levels was demonstrated after switching from sitagliptin to alogliptin. Given multiple favorable roles of adiponectin in metabolic and cardiovascular states, alogliptin, at least when combined with pioglitazone, would be beneficial in treatment of type 2 diabetes.展开更多
The new crystalline V-Ti-silicalite with mesoporous MCM-41 type molecular sieve structure is synthesized hydrothermally; The framework IR spectra associated with ESR, Si-29 MAS NMR, DRS and XPS data shows that V and T...The new crystalline V-Ti-silicalite with mesoporous MCM-41 type molecular sieve structure is synthesized hydrothermally; The framework IR spectra associated with ESR, Si-29 MAS NMR, DRS and XPS data shows that V and Ti are simultaneously incorporated into V-TiMCM-41 framework.展开更多
子宫内膜癌是女性生殖系统最常见的恶性肿瘤,近年来子宫内膜癌诊疗中备受关注的热点问题,如淋巴脉管间隙浸润的定量评价、前哨淋巴结超分期和子宫内膜癌分子分型等,已经逐渐用于临床实践。目前,子宫内膜癌相关的新进展已被写入2023版国...子宫内膜癌是女性生殖系统最常见的恶性肿瘤,近年来子宫内膜癌诊疗中备受关注的热点问题,如淋巴脉管间隙浸润的定量评价、前哨淋巴结超分期和子宫内膜癌分子分型等,已经逐渐用于临床实践。目前,子宫内膜癌相关的新进展已被写入2023版国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)子宫内膜癌分期修订版本,并在临床推广应用。规范的病理诊断是评估子宫内膜癌患者预后和指导辅助治疗的重要依据,介绍2023版FIGO子宫内膜癌分期更新对病理诊断内容的影响,旨在帮助提高病理医生子宫内膜癌病理诊断的规范化及标准化水平,辅助临床医生更准确地理解和应用新分期。展开更多
2013年美国癌症基因组图谱(The Cancer Genome Atlas,TCGA)完成了子宫内膜癌(endometrial carcinoma,EC)分子分型,将患者分为POLE(DNA polymerase epsilon)突变型、微卫星不稳定高突变(microsatellite instability-high,MSI-H)型、低拷...2013年美国癌症基因组图谱(The Cancer Genome Atlas,TCGA)完成了子宫内膜癌(endometrial carcinoma,EC)分子分型,将患者分为POLE(DNA polymerase epsilon)突变型、微卫星不稳定高突变(microsatellite instability-high,MSI-H)型、低拷贝数(copy number low,CN-L)型和高拷贝数(copy number high,CN-H)型,后西方学者改良为更贴合临床应用的ProMisE及Trans-PORTEC分型。POLE突变型患者预后较好,复发率较低,可合理减少患者手术范围,术后降级治疗,当患者合并MSI-H或CN-H时仍归为POLE突变型;MSI-H型患者肿瘤突变负荷高,免疫治疗临床获益显著;CN-L型患者最常见,预后仅次于POLE突变型患者,该类患者为保留生育功能行激素治疗缓解率较高;CN-H型患者预后最差,肿瘤具有侵袭性特征及高复发风险,对于该类患者术后需积极补充治疗,避免治疗不足,此外靶向治疗对CN-H患者疗效较好。TCGA分子分型突破了子宫内膜癌传统病理组织学分型评估预后的局限性,为子宫内膜癌的病理特征、预后及临床诊疗决策提供了全新见解。展开更多
基金supported by 2022 Special Project of Henan ProvinceChineseMedicineScientificResearch(2022ZY1048)2023 Special Project of Henan Province Chinese Medicine Scientific Research(2023YZ2043)Natural Science Foundation of Henan Province(232300421183).
文摘Objectives The objective of this study was to explore the correlation between the distribution of traditional Chinese medicine(TCM)syndromes and molecular types of breast cancer in the perichemotherapy period.Methods A total of 325 cases with perichemotherapy breast cancer was classified according to syndrome differentiation in TCM,and R×C table x2 test was used to examine and analyze the relationship between TCM syndromes and molecular types of breast cancer in the perichemotherapy period.Results(1)In the early stage of chemotherapy,there was no significant difference in the distribution of different TCM syndromes among molecular types,mainly liver depression syndrome and liver depression and phlegm coagulation syndrome(p>0.05).(2)In the middle stage of chemotherapy,there were significant differences in the distribution of spleen deficiency and phlegm-dampness syndrome among HER-2 positive(HR positive),HER-2 positive(HR negative),and Luminal Atype,Luminal B type(HER-2 negative),and triple-negative type(p<0.01).(3)After chemotherapy,there were significant differences in the distribution of spleen and kidney yang deficiency syndrome and marrow sea insufficiency syndrome among HER-2 positive(HR negative),triple-negative type,and HER-2 positive(HR positive),Luminal A type,Luminal B type(HER-2 negative),and triple-negative type(p<0.01).Conclusion(1)In the middle stage of chemotherapy,HER-2 positive(HR positive)and HER-2 positive(HR negative)are more likely to show spleen deficiency and phlegmdampness syndrome than other molecular types.(2)In the late stage of chemotherapy,the HER-2 positive(HR negative)and triple-negative type is more likely to show spleenkidney yang deficiency syndrome than other molecular types,and the triple-negative type is more likely to show marrow sea insufficiency syndrome than other molecular types.
基金Supported by the National Basic Research Program of China under Grant Nos 2015CB351902,2015CB932402 and 2012CB619203the National Natural Science Foundation of China under Grant Nos 61177070,11374295 and U1431231the National Key Research Program of China under Grant No 2011ZX01015-001
文摘Type-Ⅱ InAs/GaSb superlattiees made of 13 InAs monolayers （MLs） and 7 GaSb MLs are grown on GaSb substrates by solid source molecular beam epitaxy. To obtain lattice-matched structures, thin InSb layers are inserted between InAs and GaSb layers. We complete a series of experiments to investigate the influence of the InSb deposition time, Ⅴ/Ⅲ beam-equivalent pressure ratio and interruption time between each layer, and then characterize the superlattice （SL） structures with high-resolution x-ray diffraction and atomic force microscopy. The optimized growth parameters are applied to grow the 100-period SL structure, resulting in the full-width half-maximum of 29.55 arcsee for the first SL satellite peak and zero lattice-mismatch between the zero-order SL peak and the GaSb substrate peak.
文摘Background: There are few clinical trials addressing the difference in pleiotropic effects among dipeptidyl peptidase (DPP)-4 inhibitors. We aimed to identify difference in effects on biochemical markers of inflammation, oxidative stress, and atherosclerosis between two DPP-4 inhibitors in patients with type 2 diabetes. Methods: We prospectively observed twenty subjects with type 2 diabetes before and after a practical medication change from a treatment with pioglitazone and sitagliptin 50 mg to a combination tablet containing the same dose of pioglitazone and alogliptin 25mg, which was actually identical to switching from sitagliptin to alogliptin. After 3 months, changes from baseline in clinical data and various biochemical markers were evaluated. In particular, body mass index (BMI) and hemoglobin A1c (HbA1c) were additionally followed after 12 months for evaluation of chronic outcomes. Results: Among markers, serum levels of high molecular weight (HMW) adiponectin significantly increased from 6.9 ± 3.6 μg/ml to 8.2 ± 4.0 μg/ml (P = 0.0045). Although no clinical data changed after 3 months, significant improvements in HbA1c and BMI were observed after 12 months. Their rates of changes tended to inversely correlate with the increased percentages of serum HMW adiponectin levels during initial 3 months, but they did not reach statistical significance. Conclusions: In spite of pretreatment with pioglitazone, additional increase in serum HMW adiponectin levels was demonstrated after switching from sitagliptin to alogliptin. Given multiple favorable roles of adiponectin in metabolic and cardiovascular states, alogliptin, at least when combined with pioglitazone, would be beneficial in treatment of type 2 diabetes.
文摘The new crystalline V-Ti-silicalite with mesoporous MCM-41 type molecular sieve structure is synthesized hydrothermally; The framework IR spectra associated with ESR, Si-29 MAS NMR, DRS and XPS data shows that V and Ti are simultaneously incorporated into V-TiMCM-41 framework.
文摘子宫内膜癌是女性生殖系统最常见的恶性肿瘤,近年来子宫内膜癌诊疗中备受关注的热点问题,如淋巴脉管间隙浸润的定量评价、前哨淋巴结超分期和子宫内膜癌分子分型等,已经逐渐用于临床实践。目前,子宫内膜癌相关的新进展已被写入2023版国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)子宫内膜癌分期修订版本,并在临床推广应用。规范的病理诊断是评估子宫内膜癌患者预后和指导辅助治疗的重要依据,介绍2023版FIGO子宫内膜癌分期更新对病理诊断内容的影响,旨在帮助提高病理医生子宫内膜癌病理诊断的规范化及标准化水平,辅助临床医生更准确地理解和应用新分期。
文摘2013年美国癌症基因组图谱(The Cancer Genome Atlas,TCGA)完成了子宫内膜癌(endometrial carcinoma,EC)分子分型,将患者分为POLE(DNA polymerase epsilon)突变型、微卫星不稳定高突变(microsatellite instability-high,MSI-H)型、低拷贝数(copy number low,CN-L)型和高拷贝数(copy number high,CN-H)型,后西方学者改良为更贴合临床应用的ProMisE及Trans-PORTEC分型。POLE突变型患者预后较好,复发率较低,可合理减少患者手术范围,术后降级治疗,当患者合并MSI-H或CN-H时仍归为POLE突变型;MSI-H型患者肿瘤突变负荷高,免疫治疗临床获益显著;CN-L型患者最常见,预后仅次于POLE突变型患者,该类患者为保留生育功能行激素治疗缓解率较高;CN-H型患者预后最差,肿瘤具有侵袭性特征及高复发风险,对于该类患者术后需积极补充治疗,避免治疗不足,此外靶向治疗对CN-H患者疗效较好。TCGA分子分型突破了子宫内膜癌传统病理组织学分型评估预后的局限性,为子宫内膜癌的病理特征、预后及临床诊疗决策提供了全新见解。
